#News for #investors and #media: Today, we announced that the US Food and Drug Administration (FDA) granted approval for one of our therapies to treat adults with advanced ALK-positive non-small cell lung cancer.
Learn more: https://t.co/OqT0C3HOEP
#News for #Investors and #Media: At #TLM26 we’re unveiling our latest advancements across our hepatology pipeline for chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), and alcohol-related liver disease (ALD).
Find out more in the press release: https://t.co/7RRp0MPAgS
#TLM26
News for #Investors and #Media
Watch our CEO, Luke Miels, as he delivers news of our strong Q3 performance and continued momentum ⤵️
Find out more: https://t.co/HUq39b5AJa
#GSKResults#Earnings
#News for #Investors and #Media: Today @US_FDA has approved our first-in-class treatment for chronic hepatitis B (CHB).
This approval reflects our commitment to innovation in liver disease, where significant unmet need remains.
Learn more: https://t.co/LLiJY3C14T
#News for #Investors and #Media:
The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: https://t.co/93IMnOBBye
Building on our $30 billion commitment to US innovation, R&D and manufacturing, today we are celebrating the development of our Upper Merion Flex Factory. By expanding our presence in Pennsylvania, this factory will deliver best-in-class new medicines for respiratory disease and cancer.
@GovernorShapiro@PAChamber@TradeGov@montco_pa@ChamberPHL@SelectUSA
Hi Ravi, we're sorry to hear about your experience. We want to make sure you receive the support you need. Please log a report at https://t.co/GKnHXr2BOE or send an email to [email protected] so we can connect you with the right team. Thank you for taking the time to reach out to us.
@yolandajsmmqc Hello, thanks for contacting us. GSK does not manufacture the product you mentioned. Please contact your local doctor or healthcare provider for support.
#News for #Investors and #Media:
Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: https://t.co/ZrSf9EHCh5
@ChronicBttrfly Hi Heather, we're sorry to hear that. In the interest of patient safety, we have forwarded your comment to our safety team. Please get in touch with us at 888-825-5249 or https://t.co/rpRwoRasMG so we can learn more about the experience you reported. Thank you.
On World Hepatitis Day, we’re raising awareness of viral hepatitis and recognizing the importance of early and more complete testing in hepatitis B.
Learn more about complete testing at: https://t.co/ekh9rDyv9p
#WorldHepatitisDay#HepB#HepatitisB#LiverHealth#TestingMatters
Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.
News for #Investors and #Media
Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.
Find out more: https://t.co/GvGXOj21w6
#Q2Results $GSK
#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.
Find out more in the press release: https://t.co/SdjPEQdZc3
Our mission: to leave no person living with HIV behind.
#News for #Media and #Investors: Today @US_FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs).
With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.
Learn more: https://t.co/00v7iAtnBv
#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: https://t.co/BhBJ8aEkmL
#News for #investors and #media:
We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: https://t.co/r7yUaG73LP
#News for #investors and #media:
We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: https://t.co/cq4r2CkLYB.
Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management.
At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.